The FDA has mandated new warning labels for GLP-1 medications such as Ozempic, Wegovy, and Zepbound, highlighting a rare but serious risk of vision loss, including conditions that may lead to sudden blindness. This initiative comes after concerns were raised regarding the safety of these popular weight-loss drugs. Experts urge caution, emphasizing that while the risk is rare, patients should be aware of the potential for severe side effects. As a result, manufacturers are required to disclose information about the risk of developing eye diseases on the labels of these medications.